论文部分内容阅读
目的:探讨病毒性肝炎肝硬化患者经抗病毒治疗仍发生原发性肝癌的原因。方法:回顾性分析兰州大学第一医院东岗院区肝病中心在2012年10月-2013年6月收治的7例病毒性肝炎肝硬化患者在规范抗病毒治疗期间新发原发性肝癌的临床资料、抗病毒治疗情况。结果:7例患者中有HBV感染6例,HCV感染1例;慢性肝炎2例,肝硬化5例;HBeAg阴性5例;3例合并糖尿病;经抗病毒治疗后病毒载量均处于低度复制或不可测状态。结论:病毒性肝炎肝硬化患者经抗病毒治疗不能完全消除原发性肝癌发生的风险,病毒载量、HBeAg阴性、糖尿病、肝硬化等可能是肝癌发生的危险因素。
Objective: To investigate the causes of primary liver cancer in patients with viral hepatitis due to antiviral therapy. Methods: The clinical data of 7 patients with viral hepatitis cirrhosis who were admitted to the Center for Liver Disease of Donggang Hospital of Lanzhou University from October 2012 to June 2013 were retrospectively analyzed. The clinical data of patients with newly diagnosed primary hepatocellular carcinoma Information, antiviral treatment. Results: Among the seven patients, there were 6 cases of HBV infection, 1 case of HCV infection, 2 cases of chronic hepatitis, 5 cases of liver cirrhosis, 5 cases of HBeAg negative, 3 cases of diabetes mellitus, Or not measurable state. Conclusion: Antiviral treatment of patients with viral hepatitis and cirrhosis can not completely eliminate the risk of primary hepatocellular carcinoma. Viral load, HBeAg-negative, diabetes and cirrhosis may be the risk factors of HCC.